It will be prescribed to those who are at highest risk of serious illness.
China has given conditional approval to the importation and use of Pfizer’s Covid-19 antiviral pill Paxlovid. However, the Chinese drug regulator stated that more research is required to approve general use of the medication.
China’s National Medical Products Administration announced on Saturday that it had “conducted an emergency authorisation review”Paxlovid and the subsequently “an approval with conditions was granted for the import registration of Pfizer’s Covid-19 treatment.”
According to reports, the drug will be used in China for those suffering from a condition called a “recovery” “high risk of progression to severe disease,” according to the South China Morning Post.
Paxlovid was granted emergency authorization by the US Food and Drug Administration in December. The drug is also approved in Australia, Canada, Australia and Israel.
Pfizer anticipates that Paxlovid will generate $22 billion of revenue in 2022 alone, and the company could earn as high as $102 trillion in total revenue in this same year.
This story can be shared on social media
[ad_2]
